Alexandria Real Estate Equities, Inc. All Rights Reserved. © 2026 Table of Contents December 31, 2025 | COMPANY HIGHLIGHTS | Page | | Page | | | --- | --- | --- | --- | --- | | Alexandria's Mission and Cluster Model | iii | | | CONFERENCE CALL | | | | | | INFORMATION: | | EARNINGS PRESS RELEASE | | | | Tuesday, January 27, 2026 | | Fourth Quarter and Year Ended December 31, 2025 Financial and | | | | 2:00 p.m. Eastern Time | | Operating Results | 1 | Consolidated Statements of Operations | 8 | 11:00 a.m. Pa ...

Core Insights - FibroGen reported financial results for Q2 2025, showing total revenue of $1.3 million, an increase from $1.0 million in Q2 2024, and a net loss of $13.7 million compared to a net loss of $47.1 million in the same period last year [16][21]. Recent Developments - The company is advancing its clinical pipeline, with the Phase 2 monotherapy trial of FG-3246 expected to start in Q3 2025 [2][6]. - FibroGen reached an agreement with the FDA to advance roxadustat towards a pivotal Phase 3 trial for lower-risk myelodysplastic syndromes (LR-MDS) [2][7]. - The sale of FibroGen China to AstraZeneca is expected to close in Q3 2025 for approximately $210 million, which includes $125 million in net cash [6][7]. Financial Overview - As of June 30, 2025, FibroGen reported $23.5 million in cash and cash equivalents in the U.S. and $142.1 million in total consolidated cash [16]. - The company expects its cash runway to extend into 2028 following the sale of FibroGen China [6][16]. Upcoming Milestones - The initiation of the Phase 2 trial for FG-3246 is anticipated in Q3 2025, with topline results from an investigator-sponsored study expected in Q4 2025 [6][8]. - FibroGen plans to file the pivotal Phase 3 clinical trial protocol for roxadustat in Q4 2025 [8]. Product Development - FG-3246 is a potential first-in-class antibody-drug conjugate targeting CD46, currently in a Phase 1b/2 study in combination with enzalutamide for metastatic castration-resistant prostate cancer [11][12]. - Roxadustat is in clinical development for chemotherapy-induced anemia and is already approved in several countries for treating anemia in chronic kidney disease [13][14].

Go back to maybe even three years. And this is where a lot of people said the promise in the near term was in health care. You know, the administrative task.But the round is big. I mean, what do you need, $243 million today. Yeah, I think this this round, $243 million values the company at $1.25% billion.Now, that round is led by Oak H. CFO Andreessen Horowitz, and with participation from Openai, I think it's a testament to this platform that we've built for health systems, which liberates clinicians from t ...